Emergent BioSolutions Inc
EBS
查看详细走势图
10.920USD
+0.380+3.61%
收盘 02/06, 16:00（美东）报价延迟15分钟
575.48M总市值
7.68市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.61%
5天
-3.70%
1月
-16.96%
6月
+81.09%
今年开始到现在
-11.65%
1年
+4.40%
查看详细走势图
TradingKey Emergent BioSolutions Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Emergent BioSolutions Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名72/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.50。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Emergent BioSolutions Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Emergent BioSolutions Inc亮点
亮点风险
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
估值高估
公司最新PE估值7.68，处于3年历史高位
机构加仓
最新机构持股39.86M股，环比增加0.32%
Hotchkis & Wiley持仓
明星投资者Hotchkis & Wiley持仓，最新持仓市值880.00
分析师目标
根据
2
位分析师
买入
评级
13.500
目标均价
+28.08%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Emergent BioSolutions Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Emergent BioSolutions Inc简介
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
公司代码EBS
公司Emergent BioSolutions Inc
CEOPapa (Joseph C)
网址https://emergentbiosolutions.com/
相关品种
